Analyzing Generics Market in China 2017 - a comprehensive coverage of the Chinese generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.
China has now become the second biggest pharmaceutical market in the world. The Chinese pharmaceutical industry is expected to reach USD 167 billion by the end of 2020, growing at a CAGR of 9.1%.
In 2015, the Chinese pharmaceutical industry had a value of USD 108 billion. Generics is a major segment of the Chinese pharmaceutical industry and the government's policies are geared towards favoring a rapid growth of their generics market. The Chinese generic market is expected to surpass the US in terms of sales by the end of 2017.
The Chinese generics industry has been growing at an extremely strong rate in recent years, even though there is saturation within the overall pharmaceutical market. Generics now account for 90% of the Chinese pharmaceutical industry and the [pattern of rapid growth is expected to continue well past 2020 also.
As the government works towards making generics affordable for the general population, many leading global drug manufacturers are entering the Chinese market as they don't have to absorb the investment costs as compared to the developer of a new drug.
Analysis of the major industry players in the Chinese generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include Cipla Limited, Mylan, Sanofi SA, Teva Pharmaceutical Industries, China Grand Pharmaceutical and Healthcare Holdings and Sandoz International. This concludes this comprehensive research report.
Key Topics Covered:
A. Executive Summary
B. Analyzing the Global Generics Industry
C. Generics Industry in Asia Pacific
D. Generics Industry in China
E. Generics Industry in China: Porter's Five Forces Strategy Analysis
F. Pricing & Reimbursement in China
G. Major Industry Players
- China Grand Pharmaceutical and Healthcare Holdings Limited
- Cipla Limited
- Mylan N.V.
- Sandoz International GmbH
- Sanofi SA
- Teva Pharmaceutical Industries Limited
For more information about this report visit http://www.researchandmarkets.com/research/jqnkz4/analyzing